Crossmark

Dashing Decades of Defeat: Long Anticipated Advances in the First-line Treatment of Extensive-Stage Small Cell Lung Cancer

Published Online: 2020-02-07

Published Print: 2020-02

Authors

Armstrong, Samantha A.

Liu, Stephen V.
License Information

Text and Data Mining valid from 2020-02-01

Version of Record valid from 2020-02-01
More Information

Article History

First Online: 7 February 2020

Compliance with Ethical Standards

:

: Samantha A. Armstrong declares that she has no conflict of interest.Stephen V. Liu has received research funding from Alkermes, AstraZeneca, Bayer, Blueprint Medicines, Bristol-Myers Squibb, Clovis Oncology, Corvus Pharmaceuticals, Debiopharm, Esanex, Genentech/Roche, Eli Lilly, Lycera, Merck/MSD, Merus, Molecular Partners, Pfizer, Rain Therapeutics, RAPT Therapeutics, Spectrum, Takeda/ARIAD, Turning Point Therapeutics, and Ignyta; has received compensation from Apollomics, AstraZeneca, Bristol-Myers Squibb, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Eli Lilly, Loxo Oncology, Merck/MSD, Pfizer, PharmaMar, S.A., Regeneron Pharmaceuticals, Taiho Oncology, Takeda/ARIAD, Ignyta, and Tempus; and has received non-financial support from AstraZeneca, Genentech/Roche, and Merck/MSD.

: This article does not contain any studies with human or animal subjects performed by any of the authors.

Document is current